Emerging options for high-risk melanoma

Source: Dermatology Times, August 2020

An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.

With the increasing number of approved immunotherapies and targeted therapies for patients with stage 3 melanoma, accurate pathologic microstaging assumes increasing importance, says Giorgos Karakousis, M.D., associate professor of surgery at the Hospital of the University of Pennsylvania, Philadelphia.

“There have been ongoing discussions about the role and utility of sentinel lymph node (SLN) biopsy in patients with melanoma. But more so now than before, where a large part of the procedure’s value was prognostic, there is value in terms of helping guide decisions about effective adjuvant therapies,” he says.